AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

75 76 Next >

Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry ↗

December 26, 2023

Via Benzinga

Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies ↗

December 26, 2023

Via Benzinga

US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs ↗

December 26, 2023

Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy.

Via Benzinga

AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies ↗

December 26, 2023

AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio.

Via Benzinga

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

December 26, 2023

From AstraZeneca

Via Business Wire

Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry ↗

December 12, 2023

Via Benzinga

Health Care Company AstraZeneca Announces Acquisition of Icosavax ↗

December 12, 2023

Via Benzinga

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗

December 22, 2023

Friday, FDA approved AstraZeneca

Via Benzinga

These 3 Big Pharma Stocks Are Making Big Plays With AI ↗

December 22, 2023

Opportunity is in the air with AI, and these pharma giants are seizing the moment.

Via The Motley Fool

Topics Artificial Intelligence

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

December 21, 2023

From AstraZeneca

Via Business Wire

Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry ↗

December 21, 2023

Which weight-loss stocks are good buys today?

Via The Motley Fool

Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside ↗

December 20, 2023

RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis...

Via Benzinga

COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs ↗

December 20, 2023

COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n

Via Benzinga

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗

December 19, 2023

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the

Via Benzinga

Why Is Compugen (CGEN) Stock Up 189% Today? ↗

December 19, 2023

Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

December 18, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest? ↗

December 18, 2023

2024 is going to be a sizzler in the biopharma sector.

Via The Motley Fool

Can Altimmune's weight-loss drug be a game-changer?

December 14, 2023

The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold

Via MarketBeat

Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock ↗

December 12, 2023

Tuesday brought favorable inflation data, and bullish investors are looking for stock winners.

Via The Motley Fool

Topics Economy

Why Is Icosavax (ICVX) Stock Up 46% Today? ↗

December 12, 2023

Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 12, 2023

Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!

Via InvestorPlace

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

December 12, 2023

From AstraZeneca

Via Business Wire

AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M ↗

December 12, 2023

AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash,...

Via Benzinga

Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why ↗

December 11, 2023

Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation

Via Benzinga

AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease ↗

December 11, 2023

AstraZeneca Plc (NASDAQ: AZN)

Via Benzinga

Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis

December 10, 2023

From Alexion

Via Business Wire

AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024? ↗

December 10, 2023

It'll take a few years for its latest moves to pay off, assuming they do.

Via The Motley Fool

Topics Artificial Intelligence

Is Now the Right Time to Buy AstraZeneca Stock? ↗

December 10, 2023

The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock.

Via The Motley Fool

Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers ↗

December 07, 2023

The White House is endorsing a contentious power that permits the government to reclaim patents for specific

Via Benzinga

Topics Intellectual Property

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.